Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer.
Transgene presented two-year follow-up results from their Ph1 trial of TG4050, an individualised neoantigen therapeutic cancer vaccine, at ASCO. The data demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4050 monotherapy generated durable immune responses lasting up to two years and met all trial endpoints, including disease-free survival, immune activation and safety. Remarkably, 100% of patients treated with TG4050 remained disease-free - an exceptio...
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer Phase I part showed 100% Disease-Free Survival (DFS) after a minimum of 2-year follow-up – providing clinical proof of principle for TG4050 Randomization of all patients expected to be completed by end 2025 First immunogenicity data of Phase II part expected in H2 2026 Preliminary efficacy data expected in H2 2027 Strasbourg, France, June 19, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for th...
Transgene finalise la sélection initiale de patients pour la partie Phase II de l’essai avec TG4050 dans le cancer de la tête et du cou opérable 100 % de survie sans récidive après au moins deux ans de suivi des patients de la partie Phase I de l’essai – preuve de principe clinique démontrée pour TG4050 La randomisation des patients devrait être finalisée d’ici la fin de l’année 2025 Les premières données d’immunogénicité de la partie Phase II sont attendues au deuxième semestre 2026 Les données préliminaires d’efficacité sont attendues au deuxième semestre 2027 Strasbourg, France, 1...
A director at Kaufman & Broad sold 15,000 shares at 33.700EUR and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025, on June 16, in Boston, US;Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group), on June 18, in Paris, France; Int...
Transgene participera à plusieurs rencontres avec des acteurs clés de la biotechnologie Strasbourg (France), le 13 juin 2025, 8 h 30 – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies contre le cancer reposant sur des vecteurs viraux, annonce aujourd’hui que son équipe de direction rencontrera des investisseurs institutionnels, des scientifiques et des acteurs du monde de la biotechnologie, lors des prochaines éditions de : BIO International Convention 2025, le 16 juin 2025, à Boston (États-Unis) ;Portzamparc 2025 Mid & Small Caps Con...
BONDUELLE - Monthly statement of the number of shares and voting rights BONDUELLE Head office: "La Woestyne" - 59173 Renescure - FranceBonduelle a French S.C.A (Partnership limited by Shares) with a capital of 57 102 699,50 eurosRegistered under number : 447 250 044 (Dunkerque Commercial and Companies Register) MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE COMPANY’S SHARE CAPITAL ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FINANCIAL MARKET AUTHORITY Date of the latest informationTotal number of shares forming capitalNumber of voting rights31....
BONDUELLE - Déclaration mensuelle du nombre d'actions et de droits de vote BONDUELLE Siège social - "La Woestyne" - 59173 Renescure - FranceBonduelle SCA - Société en commandite par actions au capital de 57 102 699,50 eurosRCS DUNKERQUE 447 250 044 INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DES DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL ARTICLE 223-16 DU REGLEMENT GENERAL DE L’AUTORITE DES MARCHES FINANCIERS Date d’arrêté des informationsNombre total d’actions composant le capital Nombre total de droits de vote31.05.202532 630 114Total théorique 52 495 959 Total réel* 5...
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025 Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (see press release ). The webcast will take place on June 6, 2025 at 9:00 a.m. ET / 3:0...
Transgene organise un webinaire sur les résultats positifs de TG4050 dans les cancers de la tête et du cou présentés à l’ASCO 2025 Strasbourg, France, le 3 juin, 8h00 CET – Transgene (Euronext Paris : TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers, annonce la tenue d’un webinaire en direct pour commenter les dernières données cliniques positives de TG4050, son vaccin thérapeutique individualisé contre le cancer qui ont été présentées lors du congrès annuel 2025 de l’American Society of Clinical Oncology (ASCO)...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.